Pharma: Page 2
-
3 key FDA approval trends this year
Although approvals are off to a slow start in oncology, the agency has been living in the fast lane for neurological disorders and more.
By Kelly Bilodeau • May 8, 2023 -
A biopharma CEO opens up about executive salaries — and why he wants to change the status quo
With leaders at the biggest biopharma companies bringing in millions, the CEO of Corvus Pharmaceuticals opted for a pay cut to pour more funds into science.
By Michael Gibney • May 4, 2023 -
Explore the Trendline➔
Stock via Getty ImagesTrendlineCell and gene therapies
How the industry is overcoming hurdles in cell and gene therapy space and pushing for the next generation of treatments.
By PharmaVoice staff -
Navigating workforce challenges amid a turbulent biopharma market
A number of biopharma companies slashed their workforces this year and as market anxieties persist, more challenges could be looming.
By Karissa Waddick • May 4, 2023 -
Podcast
Woman of the Week: Jazz Pharmaceuticals’ Neena Patil
Patil’s dual interests in healthcare and law are at the intersection of her C-suite role.
By Taren Grom • May 3, 2023 -
Taking your biotech global? Here’s how you can navigate cultural norms
What’s so different about doing pharma business in the U.K. versus Japan? One of Moderna’s top brass shares her tips for navigating choppy cultural waters.
By Alexandra Pecci • May 2, 2023 -
Retrieved from Bristol Myers Squibb on April 28, 2023Making Moves
BMS’s CEO transition will be a major test for the pharma giant
Come November, Chris Boerner will take the top spot as the company approaches patent cliffs for three drugs in the next decade.
By Karissa Waddick • April 28, 2023 -
How biopharma dealmaking kicked back into action
Events over the last year, including Pfizer’s Seagen buy and AstraZeneca’s CinCor deal, have foreshadowed the comeback of biopharma M&A.
By Michael Gibney • April 27, 2023 -
Pharma’s immunology field is full of blockbusters, and it’s just getting started
From the "father" of the IL-23 pathway at Janssen to a big acquisition by Merck, the ultra-competitive immunology space is still growing with the pace of innovation.
By Michael Gibney • April 27, 2023 -
Roy Vagelos is retiring and leaving a legacy of leadership lessons
The longtime pharma leader is stepping down from his role as chair of Regeneron’s board in June after decades in drug development.
By Karissa Waddick • April 25, 2023 -
Tuberculosis is the world’s deadliest infectious disease — and treatments remain underfunded
Tuberculosis control and funding lost 20 years of progress during the COVID-19 pandemic, but scientists and world health groups are still plugging away.
By Alexandra Pecci • April 24, 2023 -
20 years on, the next stage of the human genome revolution is brewing
Two decades after the Human Genome Project, scientists are on the brink of uncovering its full potential for drug development.
By Karissa Waddick • April 24, 2023 -
Sponsored by GoodRx
A physician’s perspective on health equity, diversity and inclusion
Dr. Preeti Parikh sees parallels between promoting health equity and current DE&I challenges in the workplace.
By Preeti Parikh, MD, Executive Medical Director, GoodRx • April 24, 2023 -
Profile
The 99 seconds that changed this CEO’s life
Peter Kirk’s marathon story of inspiration and perseverance.
By Taren Grom • April 21, 2023 -
Q&A
Cure Ventures has $350M to pour deep into biotech ‘company building’
The biotech venture capital firm Cure Ventures, led by three industry veterans, raised the inaugural fund in early April and will soon announce its seed companies.
By Michael Gibney • April 20, 2023 -
Q&A
Depression has long been treated chronically — Sage wants to change that
Sage Therapeutics is planning a launch of its newest med, and its chief business officer explains how it could upend the way depression has long been treated.
By Michael Gibney • April 18, 2023 -
Patient influencers are here to stay — where are the regulations?
As social media health influencers enter the world of pharma advertising, experts warn that more guardrails are needed to protect the industry and patients.
By Karissa Waddick • April 17, 2023 -
A new era of COVID innovation is here
With a $5 billion dollar infusion, a new White House program is helping catalyze development of next-gen treatments, from pan-coronavirus vaccines to enhanced antivirals.
By Kelly Bilodeau • April 17, 2023 -
Sponsored by ProtaGene
Overcoming Analytical Challenges for Gene Therapies
Gain a deep understanding of the analytical challenges that gene therapy developers face, and how a strategic partnership with a specialized CRO can offer a competitive advantage in accelerating timelines and improving program success.
By Jennifer Chadwick, Ph.D. | Chief Scientific Officer of ProtaGene • April 17, 2023 -
Fighting vaccine hesitancy may require a new approach from pharma
The COVID-19 pandemic highlighted an ongoing problem of vaccine hesitancy undermining public health efforts. One way pharmas can help is to change the narrative.
By Michael Gibney • April 13, 2023 -
Podcast
Woman of the Week: uMotif’s Julia Lakeland
The chief product officer’s work in transforming clinical trial technology is driven by people.
By Taren Grom • April 12, 2023 -
What’s pharma doing wrong to improve trial diversity? ‘Everything’
Pharma’s missing the mark when it comes to recruiting Black patients, and Ricki Fairley, CEO of The Black Breast Cancer Alliance, reveals what’s needed.
By Karissa Waddick • April 12, 2023 -
Profile
He helped launch the Pfizer COVID vaccine — now this startup CEO is hunting a lingering pandemic foe
All of the COVID-19 mAbs have been pulled from the market. But Dave Hering, CEO of Invivyd, hopes to change that.
By Meagan Parrish • April 11, 2023 -
After working at Merck during the Vioxx scandal, this former sales rep is on a mission to fix the system
The founder and CEO for the Accreditation Council for Medical Affairs is increasing accountability in pharma by emphasizing training, standards and ethics in medical affairs.
By Alexandra Pecci • April 11, 2023 -
Sponsored by GoodRx
GoodRx Health is the one-stop-shop for patients — and marketers
Optimize patient conversion through a single platform with GoodRx: the one-stop-shop for patients — and marketers.
April 10, 2023 -
Q&A
5 minutes with — Parexel’s Peyton Howell
The company’s chief operating and growth officer on her personal quirks and why every pharma leader should read "Getting Naked."
By Taren Grom • April 7, 2023